Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients

被引:17
|
作者
Ramaekers, Bram L. T. [1 ,2 ]
Joore, Manuela A. [1 ,2 ]
Lueza, Beranger [3 ]
Bonastre, Julia [3 ]
Mauguen, Audrey [3 ]
Pignon, Jean-Pierre [3 ]
Le Pechoux, Cecile [4 ]
De Ruysscher, Dirk K. M. [5 ,6 ]
Grutters, Janneke P. C. [7 ]
机构
[1] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Hlth Serv Res, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment KEMT, NL-6202 AZ Maastricht, Netherlands
[3] Gustave Roussy, Serv Biostat & Epidemiol, Villejuif, France
[4] Gustave Roussy, Dept Oncol & Radiotherapie, Villejuif, France
[5] Maastricht Univ, Med Ctr, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, NL-6202 AZ Maastricht, Netherlands
[6] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Radiat Oncol, Louvain, Belgium
[7] Univ Med Ctr, Dept Epidemiol Biostat & HTA, Nijmegen, Netherlands
关键词
Radiotherapy; Dose fractionation; Non-small-cell lung cancer; Cost-benefit analysis; Markov chain; DOSE-ESCALATION TRIAL; CONCURRENT CHEMORADIATION; ACCELERATED RADIOTHERAPY; ECONOMIC-EVALUATION; TUMOR-CONTROL; PHASE-III; HETEROGENEITY; METAANALYSIS; SURVIVAL;
D O I
10.1097/JTO.0b013e31829f6c55
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Modified fractionation radiotherapy (RT), delivering multiple fractions per day or shortening the overall treatment time, improves overall survival for non -small-cell lung cancer (NSCLC) patients compared with conventional fractionation RT (CRT). However, its cost effectiveness is unknown. Therefore, we aimed to examine and compare the cost effectiveness of different modified RT schemes and CRT in the curative treatment of unresected NSCLC patients. Methods: A probabilistic Markov model was developed based on individual patient data from the meta-analysis of radiotherapy in lung cancer (N = 2000). Dutch health care costs, quality-adjusted life years (QALYs), and net monetary benefits (NMBs) were compared between two accelerated schemes (very accelerated RT [VART] and moderately accelerated RT [MART]), two hyperfractionated schemes (using an identical (HRTI) or higher (HRTH) total treatment dose than CRT) and CRT. Results: All modified fractionations were more effective and costlier than CRT (1.12 QALYs, Euro24,360). VART and MART were most effective (1.30 and 1.32 QALYs) and cost Euro25,746 and Euro26,208, respectively. HRTI and HRTH yielded less QALYs than the accelerated schemes (1.27 and 1.14 QALYs), and cost Euro26,199 and Euro29,683, respectively. MART had the highest NMB (Euro79,322; 95% confidence interval [CI], Euro35,478-Euro133,648) and was the most cost-effective treatment followed by VART (Euro78,347; 95% CI, Euro64,635-Euro92,526). CRT had an NMB of Euro65,125 (95% CI, Euro54,663-Euro75,537). MART had the highest probability of being cost effective (43%), followed by VART (31%), HRTI (24%), HRTH (2%), and CRT (0%). Conclusion: Implementing accelerated RT is almost certainly more efficient than current practice CRT and should be recommended as standard RT for the curative treatment of unresected NSCLC patients not receiving concurrent chemo-radiotherapy.
引用
收藏
页码:1295 / 1307
页数:13
相关论文
共 50 条
  • [1] MODIFIED FRACTIONATION RADIOTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY FOR UNRESECTED NON-SMALL CELL LUNG CANCER PATIENTS: A COST-EFFECTIVENESS ANALYSIS
    De Ruysscher, D.
    Ramaekers, B. L. T.
    Joore, M. A.
    Lueza, B.
    Bonastre, J.
    Mauguen, A.
    Pignon, J.
    Le Pechoux, C.
    Grutters, J. P.
    ANNALS OF ONCOLOGY, 2012, 23 : 397 - 397
  • [2] Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer
    Okazaki, Shohei
    Shibuya, Kei
    Takura, Tomoyuki
    Miyasaka, Yuhei
    Kawamura, Hidemasa
    Ohno, Tatsuya
    CANCER SCIENCE, 2022, 113 (02) : 674 - 683
  • [3] Meta-analysis of hypofractionated radiotherapy versus conventional radiotherapy in locally advanced non-small-cell lung cancer
    Liu, Jie
    Cheng, Hongyan
    Zhang, Chi
    Dai, Wangshu
    Ge, Xiaolin
    Xu, Liping
    Zhang, Zhaoyue
    Sun, Xinchen
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (06): : 6179 - 6188
  • [4] Non-conventional radiotherapy versus conventional radiotherapy for inoperable non-small-cell lung cancer: A meta-analysis of randomized clinical trials
    Zhang, Qiu-Ning
    Wang, Dao-Ying
    Wang, Xiao-Hu
    Hui, Tian-jin
    Yang, Ke-Hu
    Li, Zheng
    Li, Hai-Yang
    Guo, Li-Yun
    THORACIC CANCER, 2012, 3 (03) : 269 - 279
  • [5] Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial
    Saunders, M
    Dische, S
    Barrett, A
    Harvey, A
    Gibson, D
    Parmar, M
    LANCET, 1997, 350 (9072): : 161 - 165
  • [6] Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer
    Mitera, Gunita
    Swaminath, Anand
    Rudoler, David
    Seereeram, Colleen
    Giuliani, Meredith
    Leighl, Natasha
    Gutierrez, Eric
    Dobrow, Mark J.
    Coyte, Peter C.
    Yung, Terence
    Bezjak, Andrea
    Hope, Andrew J.
    JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (03) : E130 - E136
  • [7] The role of radiotherapy in non-small-cell lung cancer
    Senan, S
    Lagerwaard, FJ
    ANNALS OF ONCOLOGY, 2005, 16 : 223 - 228
  • [8] Postoperative radiotherapy in non-small-cell lung cancer
    Kal, HB
    El Sharouni, SY
    Struikmans, H
    LANCET, 1998, 352 (9137): : 1385 - 1385
  • [9] Postoperative radiotherapy in non-small-cell lung cancer
    Klages, HT
    STRAHLENTHERAPIE UND ONKOLOGIE, 1999, 175 (03) : 134 - 135
  • [10] Radical radiotherapy in non-small-cell lung cancer
    Jovanovski, D
    Smickoska, S
    Crvenkova, S
    Stojkovski, I
    2ND BALKAN CONGRESS OF ONCOLOGY, 1999, : 303 - 308